secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2023-07-19T23:59:59+00:00
Accession:  0001193125-23-189610
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma terminates Kyowa Kirin deal, regains full global rights to ME-401; urges vote for Infinity merger
--------------------------------------------------------------------------------

- Mutually terminated License, Development and Commercialization Agreement with Kyowa Kirin for ME-401 effective July 14, 2023.
- MEI regains full global rights to develop, manufacture and commercialize ME-401; Kyowa Kirin retains limited compassionate use until Nov 30, 2027.
- Each party released the other from claims; MEI must deliver certain materials to Kyowa Kirin.
- Press release reminds shareholders to vote FOR Infinity transaction at July 23 special meeting; ISS and Glass Lewis recommend FOR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000119312523189610/0001193125-23-189610-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000119312523189610/d529233d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-189610

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer